Carbonic anhydrase IX inhibitors in cancer therapy: An update

Future Medicinal Chemistry

Volumn 7, Issue 11, 2015, Pages 1407-1414

  Supuran, Claudiu T ^a   Winum, Jean Yves ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BENZENESULFONAMIDE DERIVATIVE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; COUMARIN DERIVATIVE; FLUOROURACIL; GOLD NANOPARTICLE; PACLITAXEL; SULFANILAMIDE; SULFONAMIDE; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

ANTIPROLIFERATIVE ACTIVITY; CANCER THERAPY; COLORECTAL CARCINOMA; DRUG STRUCTURE; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84938540270     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.71     Document Type: Review

References (38)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 7(2), 168-181 (2008).
2. Pastorekova S, Supuran CT. Carbonic anhydrase IX: from biology to therapy. In: Hypoxia and Cancer. Melillo G (Ed.). Humana Press, Springer Science+Business Mediam, NY, USA, 121-153 (2014).
3. Neri D, Supuran CT. Interfering with pH regulation in tumors as a therapeutic strategy. Nat. Rev. Drug Discov. 10(10), 767-77 (2011).
4. McDonald PC, Winum JY, Supuran CT et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3(1), 84-97 (2012).
5. Zatovicova M, Jelenska L, Hulikova A et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des. 16(29), 3255-3263 (2010).
6. Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin. Ther. Pat. 23(6), 737-749 (2013)
7. Poulsen SA. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007-2009. Expert Opin. Ther. Pat. 20(6), 795-806 (2010).
8. Winum JY, Rami M, Scozzafava A, Montero JL et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med. Res. Rev. 28(3), 445-463 (2008).
9. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 27(6), 759-772 (2012).
10. Winum JY, Colinas PA, Supuran C T. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg. Med. Chem. 21(6), 1419-1426 (2013).
11. Stiti M, Cecchi A, Rami M et al. Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J. Am. Chem. Soc. 130(48), 16130-1611 (2008).
12. Ratto F, Witort E, Tatini F et al. Plasmonic particles that hit hypoxic cells Adv. Funct. Mater. 25(2), 316-323 (2015).
13. Winum JY. Carbonic anhydrase inhibitors: CA IX selective inhibitors incorporating aromatic or heterocyclic sulfonamide Expert Opin. Ther. Pat. 15(2), 233-236 (2005).
14. Dubois L, Lieuwes NG, Maresca A et al. Imaging of CA IX with fuorescent labelled sulfonamides distinguishes hypoxic and (re),-oxygenated cells in a xenograft tumour model. Radiother. Oncol. 92(3), 423-428 (2009).
15. Winum JY. Carbonic anhydrase IX inhibitors: fuorescent sulfonamides as therapeutic and diagnostic agents. Expert Opin. Ther. Pat. 17(11), 1393-1396 (2007).
16. Cecchi A, Hulikova A, Pastorek J et al. Carbonic anhydrase inhibitors. Design of fuorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidifcation of hypoxic tumors. J. Med. Chem. 48(15), 4834-4841 (2005).
17. Svastová E, Hulíková A, Rafajová M et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577(3), 439-445 (2004).
18. Dubois L, Douma K, Supuran CT et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fuorescent sulfonamide inhibitors. Radiother. Oncol. 83(3), 367-373 (2007).
19. 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. Eur. J Med. Chem. 71, 374-384 (2014).
20. Akurathi V, Dubois L, Lieuwes NG et al. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nucl. Med. Biol. 37(5), 557-564 (2010)
21. Teicher BA, Liu SD, Liu JT et al. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 13 (5 A), 1549-1556 (1993).
22. Chegwidden WR, Spencer IM. Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture. Infammopharmacology 3(3), 231-239 (1995).
23. Supuran C T, Scozzafava A. Carbonic anhydrase inhibitors-Part 94. 1, 3, 4-thiadiazole-2-sulfonamidederivatives as antitumor agents? Eur. J. Med. Chem. 35(9), 867-874 (2000).
24. Supuran C T, Briganti F, Tilli S et al. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. 9(3), 703-714 (2001).
25. Ahlskog JK, Dumelin CE, Trüssel S et al. in vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett. 19(16), 4851-4856 (2009).
26. Buller F, Steiner M, Frey K et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem. Biol. 6(4), 336-344 (2011).
27. Franzini RM, Neri D, Scheuermann J. DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc. Chem. Res. 47(4), 1247-1255 (2014).
28. Pacchiano F, Carta F, McDonald PC et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 54(6), 1896-1902 (2011).
29. Lou Y, McDonald PC, Oloumi A et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71(9), 3364-3376 (2011).
30. Lock FE, McDonald PC, Lou Y et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32(44), 5210-5219 (2013).
31. ClinicalTrials Database: NCT02215850. https://clinicaltrials.gov
32. Winum JY, Carta F, Ward C et al. Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorg. Med. Chem. Lett. 22(14), 4681-4685 (2012).
33. Gieling RG, Babur M, Mamnani L et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J. Med. Chem. 55(11), 5591-5600 (2012).
34. Dubois L, Peeters S, Lieuwes NG et al. Specifc inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother. Oncol. 99(3), 424-431 (2011).
35. Rami M, Dubois L, Parvathaneni NK et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J. Med. Chem. 56(21), 8512-8520 (2013).
36. Dubois L, Peeters SG, van Kuijk SJ et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother. Oncol. 108(3), 523-528 (2013).
37. Krall N, Pretto F, Decurtins W et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew. Chem. Int. Ed. Engl. 53(16), 4231-4235 (2014).
38. Touisni N, Maresca A, McDonald PC et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem. 54(24), 8271-8277 (2011).